Loading…
The incidence of lymph node metastasis in patients with different oncogenic driver mutations among T1 non-small-cell lung cancer
•Different driver mutations have different propensity to develop lymph node metastasis.•Patients with fusion mutations have a higher risk of lymph node metastasis than other mutations.•Patients with fusion mutations present more vascular invasion compared to other mutations. To investigate the incid...
Saved in:
Published in: | Lung cancer (Amsterdam, Netherlands) Netherlands), 2019-08, Vol.134, p.218-224 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | •Different driver mutations have different propensity to develop lymph node metastasis.•Patients with fusion mutations have a higher risk of lymph node metastasis than other mutations.•Patients with fusion mutations present more vascular invasion compared to other mutations.
To investigate the incidence and distribution of lymph node metastasis in patients with different gene mutations among pathological T1 non-small-cell lung cancers (NSCLC).
NSCLC cases resected in our institution between 2016 and 2018 were included. Driver mutation testing was performed in all resected tumor tissues. These patients were grouped by the type of gene mutations. On the basis of protein that mutant-genes encoded involved in the molecular pathway, the genotypes were further classified into four distinct groups: upstream receptor mutant protein (EGFR, HER2 and MET); downstream regulator mutant protein (KRAS and BRAF); fusion mutant protein (ROS1, ALK and RET) and the wild type group. The incidence of lymph node metastasis was compared among different groups.
Of the 1052 patients enrolled, the frequency of positive mutations was 68.0%. The incidence of lymph node metastasis were as follows: wild type (19.3%), ROS1 (72.8%), BRAF (55.5%), ALK (44.7%), HER2 (40%), RET (23.1%), KRAS (15.3%), EGFR (15.3%) and MET mutation (0%) (P |
---|---|
ISSN: | 0169-5002 1872-8332 |
DOI: | 10.1016/j.lungcan.2019.06.026 |